Study of Novel Types of Familial Diabetes Insipidus
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00004364|
Recruitment Status : Unknown
Verified February 2006 by Office of Rare Diseases (ORD).
Recruitment status was: Active, not recruiting
First Posted : October 19, 1999
Last Update Posted : February 22, 2006
I. Define the phenotype and genotype of previously unrecognized types of familial diabetes insipidus (FDI) in kindreds with atypical or novel forms of FDI.
|Condition or disease||Intervention/treatment|
|Diabetes Insipidus||Drug: desmopressin|
PROTOCOL OUTLINE: Participants undergo a series of tests to determine the presence, absence, cause, natural history, clinical status, and mode of inheritance of their type of diabetes insipidus (DI). The studies include measurements of basal fluid intake and urine output, plasma vasopressin during standard fluid deprivation or waterload/saline infusion tests, and changes in water balance during a therapeutic trial of DDAVP. If clinically indicated, echocardiograms and assays of plasma catecholes and renin are also completed.
Linkage analysis is performed for all participants; kindreds with the Marfan-like syndrome are also studied for the fibrillin-1 genotype.
Participants determined to have DI are treated with desmopressin for 2 days.
|Study Type :||Observational|
|Estimated Enrollment :||5 participants|
|Study Start Date :||December 1995|
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00004364
|Study Chair:||Gary L. Robertson||Northwestern University|